ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy

• ProteinLogic, Cambridge, UK and Stellenbosch University, South Africa collaboration study funded by Bill & Melinda Gates Foundation.
• ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring.
• ProteinLogic ImmiPrint® diagnostic pattern of soluble immune proteins in blood and other body fluids portfolio defined using machine learning.
• ImmiPrint® off-the-shelf diagnostics and disease progression monitoring tests address multiple disease areas including infectious diseases and oncology.
• ImmiPrint® technology applicable to resource-rich and emerging economy clinical settings.

CAMBRIDGE, UK (2024-01-22): ProteinLogic, a biomarker discovery and commercialization company and Stellenbosch University, today announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy. The collaborative project was conceived and developed with the assistance of PTNG Consulting, a specialised science consultancy. PTNG Consulting will oversee the project management of this undertaking.